QCG
TAK icon

Quadrant Capital Group’s Takeda Pharmaceutical TAK Stock Holding History

Quadrant Capital Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31M Sell
81,606
-45,899
-36% -$760K 0.04% 472
2026
Q1 		$2.36M Buy
127,505
+46,487
+57% +$816K 0.07% 223
2025
Q4 		$1.26M Buy
81,018
+33,235
+70% +$475K 0.04% 441
2025
Q3 		$700K Sell
47,783
-79,938
-63% -$1.19M 0.02% 688
2025
Q2 		$1.97M Sell
127,721
-34,259
-21% -$506K 0.07% 231
2025
Q1 		$2.41M Buy
161,980
+143,774
+790% +$2.01M 0.09% 142
2024
Q4 		$241K Buy
18,206
+6,595
+57% +$90.6K 0.02% 588
2024
Q3 		$165K Buy
11,611
+2,049
+21% +$29.1K 0.01% 803
2024
Q2 		$124K Sell
9,562
-5,561
-37% -$73.6K 0.01% 886
2024
Q1 		$210K Sell
15,123
-2,100
-12% -$30.5K 0.02% 597
2023
Q4 		$246K Sell
17,223
-2,506
-13% -$35.6K 0.02% 516
2023
Q3 		$305K Sell
19,729
-4,446
-18% -$68.8K 0.03% 388
2023
Q2 		$380K Sell
24,175
-2,826
-10% -$46.3K 0.04% 326
2023
Q1 		$445K Buy
27,001
+8,041
+42% +$128K 0.05% 294
2022
Q4 		$296K Sell
18,960
-143
-0.7% -$2K 0.03% 372
2022
Q3 		$248K Buy
19,103
+1,214
+7% +$16.9K 0.03% 360
2022
Q2 		$251K Sell
17,889
-2,119
-11% -$30.2K 0.03% 362
2022
Q1 		$287K Buy
20,008
+2,803
+16% +$41.2K 0.03% 355
2021
Q4 		$235K Buy
17,205
+9,622
+127% +$135K 0.03% 397
2021
Q3 		$124K Sell
7,583
-3,269
-30% -$54.9K 0.02% 545
2021
Q2 		$183K Buy
10,852
+376
+4% +$6.4K 0.03% 412
2021
Q1 		$191K Buy
10,476
+1,129
+12% +$20.3K 0.03% 362
2020
Q4 		$170K Sell
9,347
-2,111
-18% -$37K 0.03% 351
2020
Q3 		$204K Buy
11,458
+3,982
+53% +$72.5K 0.04% 258
2020
Q2 		$134K Sell
7,476
-43,752
-85% -$785K 0.03% 369
2020
Q1 		$779K Sell
51,228
-842
-2% -$15.3K 0.13% 135
2019
Q4 		$1.01M Buy
52,070
+20,657
+66% +$395K 0.12% 124
2019
Q3 		$532K Buy
31,413
+278
+0.9% +$4.81K 0.08% 223
2019
Q2 		$543K Buy
31,135
+7,051
+29% +$128K 0.09% 206
2019
Q1 		$476K Buy
24,084
+10,942
+83% +$220K 0.08% 206
2018
Q4 		$216K Buy
+13,142
New +$222K 0.06% 322

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Quadrant Capital Group's TAK Position: Q2 2026 in Review

Quadrant Capital Group reduced its Takeda Pharmaceutical (TAK) stake by 36% in Q2 2026, selling an estimated $760K and leaving 81,606 shares worth $1.31M. The position accounts for 0.04% of the portfolio, ranked #472.

Quadrant Capital Group first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $2.41M in Q1 2025. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Quadrant Capital Group held 81,606 shares of Takeda Pharmaceutical worth $1.31M as of Q2 2026.
  • Quadrant Capital Group sold 45,899 Takeda Pharmaceutical shares in Q2 2026, an estimated $760K.
  • Takeda Pharmaceutical made up 0.04% of Quadrant Capital Group's portfolio in Q2 2026, its #472 holding.
  • Quadrant Capital Group first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
  • Quadrant Capital Group's Takeda Pharmaceutical position peaked at $2.41M in Q1 2025.
  • 376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.